Back to Main

Faculty Detail    
Name MATTHEW MIGHT
Director, Hugh Kaul Precision Medicine Institute at UAB
 
Campus Address KAUL 202A Zip 3412
Phone  (20-5) -489
E-mail  might@uab.edu
Other websites
     

Education
Undergraduate  Georgia Institute of Technology    2001  BS, Computer Science 
Graduate  Georgia Institute of Technology    2003  MS, Computer Science 
Graduate  Georgia Institute of Technology    2007  PhD, Computer Science 


Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Medicine  GIM-Precision Medicine Professor

Biographical Sketch 
Matthew Might, Ph.D., was named the inaugural director of the Hugh Kaul Precision Medicine Institute at UAB in July 2017. A strategic leader appointed to the White House Precision Medicine Initiative by former President Barack Obama, Might’s research interests focus on the intersection of computation and medicine to advance precision medicine through personalized therapeutics. Might is visiting faculty in the Department of Biomedical Informatics at Harvard Medical School. He was previously a faculty member at the University of Utah, where he was a Presidential Scholar and an associate professor in both computer science and pharmaceutical chemistry.



Research/Clinical Interest
Title
Precision Medicine
Description
In medicine, my primary research area is precision medicine -- the use of data (particularly genomic data) to personalized treatments and optimize healthcare outcomes. I am particularly interested in drug repurposing. In computer science, my primary research area is static analysis of higher-order programs, although I also do work in functional programming, relational programming, parsing and purely functional data structures. My broader interests include language design, compiler implementation, security, program optimization, parallelism and program verification.

Selected Publications 
Publication PUBMEDID
The Undiagnosed Diseases Network: Accelerating Discovery about Health and Disease. Am J Hum Genet. 2017 Feb 2;100(2):185-192. doi: 10.1016/j.ajhg.2017.01.006.  28157539 
Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.Bioorg Med Chem Lett. 2017 Jul 1;27(13):2962-2966. doi: 10.1016/j.bmcl.2017.05.010. Epub 2017 May 5.  28512024 
Transcriptome and functional analysis in a Drosophila model of NGLY1 deficiency provides insight into therapeutic approaches. Hum Mol Genet. 2018 Mar 15;27(6):1055-1066. doi: 10.1093/hmg/ddy026.  29346549 
A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy. Epilepsia. 2018 Apr;59(4):802-813. doi: 10.1111/epi.14037. Epub 2018 Mar 25.  29574705 
Plain-language medical vocabulary for precision diagnosis. Nat Genet. 2018 Apr;50(4):474-476. doi: 10.1038/s41588-018-0096-x.  29632381